2.25  -0.2 (-8.16%)		01-09 16:00
Open: 2.44 High: 2.44 Volume: 131,088		Pre. Close: 2.45 Low: 2.23 Market Cap: 6(M)

Short term
Mid term
Targets	6-month :	2.91	1-year :	3.41
Resists	First :	2.49	Second :	2.91
Pivot price	2.13
Supports	First :	1.88	Second :	1.5
MAs	MA(5) :	2.27	MA(20) :	2.13
	MA(100) :	3.02	MA(250) :	2.91
MACD	MACD :	-0.1	Signal :	-0.2
%K %D	K(14,3) :	86.2	D(3) :	82.4
RSI	RSI(14): 48.9
52-week	High :	6.9	Low :	1.5

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ CELZ ] has closed below upper band by 32.1%. Bollinger Bands are 34.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	2.44 - 2.45	2.45 - 2.46
Low:	2.2 - 2.22	2.22 - 2.23
Close:	2.23 - 2.25	2.25 - 2.27

Creative Medical Technology Holdings, Inc., a biotechnology company, focuses on immunology, urology, orthopedics, and neurology using adult stem cell treatments. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; StemSpine to treat chronic lower back pain; ImmCelz for the treatment of stroke patients; and OvaStem for treatment of female infertility. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.

Tue, 06 Jan 2026
Creative Medical (CELZ) Gains Approval for Veteran Health Initia - GuruFocus

Tue, 06 Jan 2026
Creative Medical’s BioDefense initiative receives regulatory approval - Investing.com

Tue, 06 Jan 2026
Creative Medical Technology Holdings Receives Regulatory Approval for BioDefense Burn Pit Initiative - The Manila Times

Tue, 06 Jan 2026
Creative Medical Technology Holdings, Inc. Receives Regulatory Approval for BioDefense Inc. Burn Pit Initiative to Aid Veterans - Quiver Quantitative

Tue, 06 Jan 2026
New burn pit program uses AI and stem cells to study veterans’ toxic exposure - Stock Titan

Wed, 31 Dec 2025
Creative Medical Technology stockholders approve warrant exercise proposal - Investing.com

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Outperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	3 (M)
Held by Insiders	2.38e+006 (%)
Held by Institutions	1 (%)
Shares Short	43 (K)
Shares Short P.Month	0 (K)

EPS	-5.97e+006
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	-101 %
Return on Assets (ttm)	379.4 %
Return on Equity (ttm)	-59.7 %
Qtrly Rev. Growth	6000 %
Gross Profit (p.s.)	0
Sales Per Share	-16.75
EBITDA (p.s.)	614.33
Qtrly Earnings Growth	-2.9 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	-6 (M)

PE Ratio	-0.01
PEG Ratio	0
Price to Book value	0
Price to Sales	-0.14
Price to Cash Flow	6.07

Dividend	0
Forward Dividend	77020
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.